Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). ASCO-GU 2019, abstract 545.
Klinische respons als primair eindpunt van de OSTRICh-studie
jan 2019 | Uro-oncologie